Jaffetilchin Investment Partners LLC grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 16,916 shares of the company’s stock after acquiring an additional 670 shares during the quarter. Jaffetilchin Investment Partners LLC’s holdings in Johnson & Johnson were worth $2,518,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. Newfound Research LLC acquired a new position in Johnson & Johnson during the 3rd quarter worth approximately $28,000. Islay Capital Management LLC acquired a new position in Johnson & Johnson during the 2nd quarter worth approximately $42,000. FAI Wealth Management boosted its position in Johnson & Johnson by 45.9% during the 2nd quarter. FAI Wealth Management now owns 321 shares of the company’s stock worth $45,000 after acquiring an additional 101 shares during the last quarter. SeaBridge Investment Advisors LLC boosted its position in Johnson & Johnson by 160.0% during the 2nd quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock worth $46,000 after acquiring an additional 200 shares during the last quarter. Finally, HWG Holdings LP acquired a new position in Johnson & Johnson during the 2nd quarter worth approximately $49,000. 67.44% of the stock is owned by hedge funds and other institutional investors.
Shares of Johnson & Johnson stock opened at $146.36 on Friday. The business has a fifty day simple moving average of $145.51 and a two-hundred day simple moving average of $146.57. Johnson & Johnson has a 1 year low of $109.16 and a 1 year high of $157.00. The company has a market capitalization of $385.30 billion, a price-to-earnings ratio of 23.01, a P/E/G ratio of 3.04 and a beta of 0.69. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.48 and a quick ratio of 1.24.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.22. The business had revenue of $21.08 billion during the quarter, compared to the consensus estimate of $20.15 billion. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The company’s quarterly revenue was up 1.7% on a year-over-year basis. During the same quarter last year, the firm posted $2.12 EPS. As a group, equities analysts anticipate that Johnson & Johnson will post 7.99 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a dividend of $1.01 per share. This represents a $4.04 annualized dividend and a yield of 2.76%. The ex-dividend date is Monday, November 23rd. Johnson & Johnson’s payout ratio is 46.54%.
JNJ has been the subject of a number of recent research reports. Cantor Fitzgerald upped their price target on Johnson & Johnson from $168.00 to $180.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 14th. ValuEngine raised Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Monday, August 3rd. Stifel Nicolaus downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, August 19th. Credit Suisse Group increased their price objective on Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a report on Wednesday, October 14th. Finally, Raymond James reissued a “buy” rating on shares of Johnson & Johnson in a report on Friday. One research analyst has rated the stock with a sell rating, four have given a hold rating and ten have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $164.93.
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,115 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the transaction, the executive vice president now owns 66,658 shares in the company, valued at approximately $10,233,336.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.27% of the stock is owned by company insiders.
Johnson & Johnson Company Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Recommended Story: NASDAQ
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.